Literature DB >> 29455196

The Relationship between Hypomagnesemia and Pulmonary Function Tests in Patients with Chronic Asthma.

Hatice Kılıc1, Asiye Kanbay2, Ayşegul Karalezlı1, Elif Babaoglu1, H Canan Hasanoglu3, Ozcan Erel4, Can Ates5.   

Abstract

OBJECTIVE: To investigate the relationship between serum values of magnesium and the parameters of the pulmonary function tests (PFT) in patients with chronic asthma. SUBJECTS AND METHODS: This study recruited 50 patients with chronic stable asthma and 40 healthy individuals as a control group. Data on age, sex, severity of asthma, PFT, and details of drug therapy were obtained from each group. Serum magnesium, potassium, phosphorus, calcium, and sodium levels were also measured. To evaluate differences between groups, the Student t test or Mann-Whitney U test was performed for continuous variables, and the χ2 test for categorical variables.
RESULTS: In the asthma group, 10% (n = 9) of the patients had hypomagnesemia and 5.5% (n = 5) had hypophosphatemia. Patients with asthma were divided into two groups: the hypomagnesemic group (n = 9) and the normomagnesemic group (n = 41). Forced expiratory volume in 1 s (FEV1), FEV1%, peak expiratory flow (PEF), and PEF% were lower in the hypomagnesemic group than in the normomagnesemic group (p = 0.02). Multiple logistic regression analysis revealed a statistically significant association between hypomagnesemia and PFT in the hypomagnesemic asthmatic group. The correlations of age with FEV1, FEV1%, PEF, and PEF% were as follows: p = 0.00, r = 0.29; p = 0.00, r = 0.43; p = 0.03, r = 0.22; p = 0.00, r = 0.38; and p = 0.03, r = 0.22, respectively. The correlation of serum magnesium levels with PFT (FEV1, FEV1%, PEF, PEF%) were as follows: p = 0.001, r = 0.29; p = 0.001, r = 0.43; p = 0.03, r = 0.22; and p = 0.001, r = 0.38, respectively. The other electrolytes were within the normal range in both groups.
CONCLUSION: In this study, hypomagnesemia and hypophosphatemia were found to be the most common electrolyte abnormalities in patients with chronic stable asthma. FEV1, FEV1%, PEF, and PEF% were significantly lower in asthmatic patients with hypomagnesemia compared to asthmatic patients with normomagnesemia. ©2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Asthma; FEV1; Hypomagnesemia; Hypophosphatemia; Pulmonary function test; β2-agonists

Mesh:

Year:  2018        PMID: 29455196      PMCID: PMC5968247          DOI: 10.1159/000487760

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  25 in total

1.  Hypomagnesaemia in chronic, stable asthmatics: prevalence, correlation with severity and hospitalization.

Authors:  O S Alamoudi
Journal:  Eur Respir J       Date:  2000-09       Impact factor: 16.671

2.  Asthma diagnosis and management.

Authors:  Ariana Murata; Patrick M Ling
Journal:  Emerg Med Clin North Am       Date:  2011-12-07       Impact factor: 2.264

3.  Investigation of the effect of short-term change in dietary magnesium intake in asthma.

Authors:  J Hill; A Micklewright; S Lewis; J Britton
Journal:  Eur Respir J       Date:  1997-10       Impact factor: 16.671

4.  Bronchial reactivity and dietary antioxidants.

Authors:  A Soutar; A Seaton; K Brown
Journal:  Thorax       Date:  1997-02       Impact factor: 9.139

5.  Effect of MgSO₄ on FEV₁ in stable severe asthma patients with chronic airflow limitation.

Authors:  Alinda M G Zandsteeg; Petra Hirmann; Henk R Pasma; Jan-Peter Yska; Anneke ten Brinke
Journal:  Magnes Res       Date:  2009-12       Impact factor: 1.115

6.  Electrolyte disturbances in patients with chronic, stable asthma: effect of therapy.

Authors:  O S Alamoudi
Journal:  Chest       Date:  2001-08       Impact factor: 9.410

Review 7.  Personalised Medicine for Asthma and Chronic Obstructive Pulmonary Disease.

Authors:  Liam G Heaney; Lorcan P A McGarvey
Journal:  Respiration       Date:  2017-01-21       Impact factor: 3.580

8.  Oral magnesium and vitamin C supplements in asthma: a parallel group randomized placebo-controlled trial.

Authors:  A Fogarty; S A Lewis; S L Scrivener; M Antoniak; S Pacey; M Pringle; J Britton
Journal:  Clin Exp Allergy       Date:  2003-10       Impact factor: 5.018

9.  Bronchial reactivity and intracellular magnesium: a possible mechanism for the bronchodilating effects of magnesium in asthma.

Authors:  L J Dominguez; M Barbagallo; G Di Lorenzo; A Drago; S Scola; G Morici; C Caruso
Journal:  Clin Sci (Lond)       Date:  1998-08       Impact factor: 6.124

10.  The cost of asthma in Kuwait.

Authors:  Mousa Khadadah
Journal:  Med Princ Pract       Date:  2012-08-08       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.